In the B16 melanoma concomitant tumor immunity model developed by Turk et. al. [31], concomitant tumor immunity was observed only after manipulating B16 melanoma cells to express GM-CSF, or by depleting/inhibiting regulatory T cells. Here, CSF2 is linked to neoplasm.